 All patients with Retinal Vein Occlusion RVO with available initial imaging and documented treatment failure with bevacizumab, ranibizumab, or aflibercept. Treatment failure is defined as lack of anatomic improvement persistent intraretinal cystic changesmacular edema with central subfield thickness greater than 250 microns on time-domain OCT or greater than 275 microns on spectral domain OCT with lack of visual improvement less than 2 lines of visual gain by Snellen acuity, despite 3 to 6 intravitreal anti-VEGF treatments over the preceding 6 months. 